These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32714571)

  • 1. Specific targeting of IL-1β activity to CD8
    Van Den Eeckhout B; Van Hoecke L; Burg E; Van Lint S; Peelman F; Kley N; Uzé G; Saelens X; Tavernier J; Gerlo S
    NPJ Vaccines; 2020; 5(1):64. PubMed ID: 32714571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus.
    Kayamuro H; Yoshioka Y; Abe Y; Arita S; Katayama K; Nomura T; Yoshikawa T; Kubota-Koketsu R; Ikuta K; Okamoto S; Mori Y; Kunisawa J; Kiyono H; Itoh N; Nagano K; Kamada H; Tsutsumi Y; Tsunoda S
    J Virol; 2010 Dec; 84(24):12703-12. PubMed ID: 20881038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
    Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
    J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice.
    Russell RF; McDonald JU; Lambert L; Tregoning JS
    J Virol; 2016 May; 90(9):4735-4744. PubMed ID: 26912628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broadly Protective CD8
    Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
    J Virol; 2021 May; 95(12):. PubMed ID: 33827939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Interleukin-33-Group 2 Innate Lymphoid Cell Axis Represents a Potential Adjuvant Target To Increase the Cross-Protective Efficacy of Influenza Vaccine.
    Williams CM; Roy S; Califano D; McKenzie ANJ; Metzger DW; Furuya Y
    J Virol; 2021 Oct; 95(22):e0059821. PubMed ID: 34468174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of Robust Immune Responses by CpG-ODN-Loaded Hollow Polymeric Nanoparticles for Antiviral and Vaccine Applications in Chickens.
    Lin SY; Yao BY; Hu CJ; Chen HW
    Int J Nanomedicine; 2020; 15():3303-3318. PubMed ID: 32494131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection.
    Kim YH; Bang YJ; Park HJ; Li Ko H; Park SI; Hwang KA; Kim H; Nam JH
    Vaccine; 2020 Sep; 38(39):6141-6152. PubMed ID: 32739118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
    Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
    Altenburg AF; van de Sandt CE; van Trierum SE; De Gruyter HLM; van Run PRWA; Fouchier RAM; Roose K; Saelens X; Volz A; Sutter G; de Vries RD; Rimmelzwaan GF
    J Virol; 2016 Nov; 90(22):10209-10219. PubMed ID: 27581985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal immunization with an adenoviral vector vaccine confers superior protection against RSV compared to natural immunity.
    Maier C; Fuchs J; Irrgang P; Wißing MH; Beyerlein J; Tenbusch M; Lapuente D
    Front Immunol; 2022; 13():920256. PubMed ID: 36003372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The RNA- and TRIM25-Binding Domains of Influenza Virus NS1 Protein Are Essential for Suppression of NLRP3 Inflammasome-Mediated Interleukin-1β Secretion.
    Moriyama M; Chen IY; Kawaguchi A; Koshiba T; Nagata K; Takeyama H; Hasegawa H; Ichinohe T
    J Virol; 2016 Apr; 90(8):4105-4114. PubMed ID: 26865721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy.
    Demento SL; Eisenbarth SC; Foellmer HG; Platt C; Caplan MJ; Mark Saltzman W; Mellman I; Ledizet M; Fikrig E; Flavell RA; Fahmy TM
    Vaccine; 2009 May; 27(23):3013-21. PubMed ID: 19428913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-1β as mucosal vaccine adjuvant: the specific induction of tissue-resident memory T cells improves the heterosubtypic immunity against influenza A viruses.
    Lapuente D; Storcksdieck Genannt Bonsmann M; Maaske A; Stab V; Heinecke V; Watzstedt K; Heß R; Westendorf AM; Bayer W; Ehrhardt C; Tenbusch M
    Mucosal Immunol; 2018 Jul; 11(4):1265-1278. PubMed ID: 29545648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Adjuvants Enhance Recombinant Protein Vaccine Protection against Fungal Infection.
    Wüthrich M; Dobson HE; Ledesma Taira C; Okaa UJ; Dos Santos Dias L; Isidoro-Ayza M; Petrovsky N; Klein BS
    mBio; 2021 Aug; 12(4):e0201821. PubMed ID: 34399628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.